Polo-like kinase 1 is a potential therapeutic target in human melanoma

Journal of Investigative Dermatology

Volumn 131, Issue 9, 2011, Pages 1886-1895

  Jalili, Ahmad ^a   Moser, Anna ^a   Pashenkov, Mikhail ^a,d   Wagner, Christine ^a   Pathria, Gaurav ^a   Borgdorff, Viola ^a,b   Gschaider, Melanie ^a   Stingl, Georg ^a   Ramaswamy, Sridhar ^c   Wagner, Stephan N ^a,b  

^a Universitatsklinik fur Dermatologie   (Austria)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d INSTITUTE OF IMMUNOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CASPASE 3; CASPASE 8; MITOGEN ACTIVATED PROTEIN KINASE; POLO LIKE KINASE 1; PROTEIN BCL 2; PROTEIN BID; PROTEIN P53; SORAFENIB;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VITRO STUDY; MELANOCYTIC NEVUS; MELANOMA; METASTASIS; MOLECULAR DYNAMICS; PRIMARY MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 80051785314     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.136     Document Type: Article

References (44)

1. Archambault V, Glover DM (2009) Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 10:265-75
2. Barr FA, Silljé HH, Nigg EA (2004) Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 5:429-40 (Pubitemid 38745493)
3. Bollag G, Hirth P, Tsai J et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-9
4. Cheng KY, Lowe ED, Sinclair J et al. (2003) The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex. EMBO J 22:5757-68 (Pubitemid 37408815)
5. Chopra P, Sethi G, Dastidar SG et al. (2010) Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert Opin Investig Drugs 19:27-43
6. Clark EA, Golub TR, Lander ES et al. (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532-5 (Pubitemid 30625739)
7. Dabrowska-Iwanicka A, Olszewska D, Jalili A et al. (2002) Augmented antitumour effects of combination therapy with TNP-470 and chemoim-munotherapy in mice. J Cancer Res Clin Oncol 128:433-42 (Pubitemid 35007554)
8. Degenhardt Y, Lampkin T (2010) Targeting polo-like kinase in cancer therapy. Clin Cancer Res 16:384-9
9. Eom YW, Kim MA, Park SS et al. (2005) Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 24:4765-77 (Pubitemid 41076294)
10. Fecher LA, Amaravadi RK, Flaherty KT (2008) The MAPK pathway in melanoma. Curr Opin Oncol 20:183-9 (Pubitemid 351317406)
11. Flaherty KT, Hodi FS, Bastian BC (2010a) Mutation-driven drug development in melanoma. Curr Opin Oncol 22:178-83
12. Flaherty KT, Puzanov I, Kim KB et al. (2010b) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-19
13. Flaherty KT, Smalley KS (2009) Preclinical and clinical development of targeted therapy in melanoma: attention to schedule. Pigment Cell Melanoma Res 22:529-31
14. Garbe C, Peris K, Hauschild A et al. (2010) Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 46:270-83
15. Gleixner KV, Ferenc V, Peter B et al. (2010) Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res 70:1513-23
16. Golsteyn RM, Mundt KE, Fry AM et al. (1995) Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J Cell Biol 129:1617-28
17. Goto H, Tomono Y, Ajiro K et al. (1999) Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation. J Biol Chem 274:25543-9
18. Gray PJ Jr, Bearss DJ, Han H et al. (2004) Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther 3:641-6 (Pubitemid 39193743)
19. Guan R, Tapang P, Leverson JD et al. (2005) Small interfering RNA-mediated polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 65:2698-704 (Pubitemid 40490070)
20. Haass NK, Sproesser K, Nguyen TK et al. (2008) The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 14:230-9 (Pubitemid 351378000)
21. Hartman M, Loy EY, Ku CS et al. (2010) Molecular epidemiology and its current clinical use in cancer management. Lancet Oncol 11:383-90
22. He ZL, Zheng H, Lin H et al. (2009) Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World J Gastroenterol 15:4177-82
23. Hofheinz RD, Al-Batran SE, Hochhaus A et al. (2010) Open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, given in two treatment schedules in patients with advanced solid tumors. Clin Cancer Res 16:4666-74
24. Ikediobi ON, Davies H, Bignell G et al. (2006) Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 5:2606-12 (Pubitemid 44848987)
25. Kneisel L, Strebhardt K, Bernd A et al. (2002) Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 29:354-8
26. Koo HM, VanBrocklin M, McWilliams MJ et al. (2002) Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci USA 99:3052-7 (Pubitemid 34240584)
27. Kwong L, Chin L, Wagner SN (2007) Growth factors and oncogenes as targets in melanoma: lost in translation? Adv Dermatol 23:99-129
28. Lee J, Hong F, Kwon S et al. (2002) Activation of p38 MAPK induces cell cycle arrest via inhibition of Raf/ERK pathway during muscle differentiation. Biochem Biophys Res Commun 298:765-71 (Pubitemid 35356806)
29. Linos E, Swetter SM, Cockburn MG (2009) Increasing burden of melanoma in the United States. J Invest Dermatol 129:1666-74
30. Liu X, Erikson RL (2003) Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 100:5789-94 (Pubitemid 36576886)
31. Lotze MT, Dallal RM, Kirkwood JM, Flickinger JC (2001) Cutaneous melanoma. In: Cancer: principles & practice of oncology. HS DeVita VT Jr, Rosenberg SA (eds). Philadelphia, PA, Lippincott Williams & Wilkins, 2012-69
32. Pumiglia KM, Decker SJ (1997) Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc Natl Acad Sci USA 94:448-52 (Pubitemid 27053653)
33. Schmit TL, Zhong W, Nihal M et al. (2009a) Polo-like kinase 1 (Plk1) in non-melanoma skin cancers. Cell Cycle 8:2697-702
34. Schmit TL, Zhong W, Setaluri V et al. (2009b) Targeted depletion of polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol 129:2843-53
35. Smalley KS (2010) PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Curr Opin Investig Drugs 11:699-706
36. Smith MR, Wilson ML, Hamanaka R et al. (1997) Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 234:397-405 (Pubitemid 27243915)
37. Strebhardt K, Kneisel L, Linhart C et al. (2000) Prognostic value of pololike kinase expression in melanomas. JAMA 283:479-80 (Pubitemid 30062860)
38. Subramanian J, Simon R (2010) Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 102:464-74
39. Takahashi T, Sano B, Nagata T et al. (2003) Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 94:148-52 (Pubitemid 36575873)
40. Wäsch R, Hasskarl J, Schnerch D et al. (2010) BI2536-targeting the mitotic kinase polo-like kinase 1 (Plk1). Recent Results Cancer Res 184:215-8
41. Weichert W, Kristiansen G, Schmidt M et al. (2005) Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol 11:5644-50 (Pubitemid 41684917)
42. Weichert W, Schmidt M, Gekeler V et al. (2004) Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 60:240-5 (Pubitemid 38971835)
43. Whitfield ML, Sherlock G, Saldanha AJ et al. (2002) Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13:1977-2000 (Pubitemid 34651487)
44. Xu L, Shen SS, Hoshida Y et al. (2008) Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res 6:760-9